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Abstract
Vector capsid dose-dependent inflammation of transduced liver has limited the ability of adeno-associated virus (AAV)
factor IX (FIX) gene therapy vectors to reliably convert severe to mild hemophilia B in human clinical trials. These trials
also identified the need to understand AAV neutralizing antibodies and empty AAV capsids regarding their impact on
clinical success. To address these safety concerns, we have used a scalable manufacturing process to produce GMP-
grade AAV8 expressing the FIXR338L gain-of-function variant with minimal ( <10%) empty capsid and have per-
formed comprehensive dose–response, biodistribution, and safety evaluations in clinically relevant hemophilia models.
The scAAV8.FIXR338L vector produced greater than 6-fold increased FIX specific activity compared with wild-type
FIX and demonstrated linear dose responses from doses that produced 2–500% FIX activity, associated with dose-
dependent hemostasis in a tail transection bleeding challenge. More importantly, using a bleeding model that closely
mimics the clinical morbidity of hemophilic arthropathy, mice that received the scAAV8.FIXR338L vector developed
minimal histopathological findings of synovitis after hemarthrosis, when compared with mice that received identical
doses of wild-type FIX vector. Hemostatically normal mice (n = 20) and hemophilic mice (n = 88) developed no FIX
antibodies after peripheral intravenous vector delivery. No CD8+ T cell liver infiltrates were observed, despite the
marked tropism of scAAV8.FIXR338L for the liver in a comprehensive biodistribution evaluation (n = 60 animals).
With respect to the role of empty capsids, we demonstrated that in vivo FIXR338L expression was not influenced by the
presence of empty AAV particles, either in the presence or absence of various titers of AAV8-neutralizing antibodies.
Necropsy of FIX–/– mice 8–10 months after vector delivery revealed no microvascular or macrovascular thrombosis in
mice expressing FIXR338L (plasma FIX activity, 100–500%). These preclinical studies demonstrate a safety:efficacy
profile supporting an ongoing phase 1/2 human clinical trial of the scAAV8.FIXR338L vector (designated BAX335).
Introduction
Hemophilia B is an X-linked congenital bleeding dis-order that results from deficient activity of clotting
factor IX. In the severe form it may be complicated by re-
current potentially crippling joint and muscle bleeding and,
less frequently, by life-threatening hemorrhage including
bleeding into the central nervous system. Factor IX protein
replacement by regular intravenous infusion is effective;
however, treatment is cumbersome, extraordinarily expensive,
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and only widely available to the estimated 20% of the world’s
hemophilic individuals who live in more economically re-
sourced countries.1 Gene therapy for hemophilia has been a
prized but elusive goal of the biomedical research community.
A human clinical trial conducted between 2001 and 2004
provided proof of concept that viral vectors based on the
nonpathogenic dependovirus adeno-associated virus (AAV)
can successfully deliver the factor IX gene to the liver.2 This
trial established the research pathway for the last decade of
effort toward a cure. In that phase 1/2 dose-escalation trial
reported by Manno and colleagues, which employed a single-
stranded DNA vector based on AAV serotype 2 (for which
humans are the natural host), two lower vector doses were
shown to be safe but did not result in measurable factor IX
expression. Escalation to the planned highest dose (2 · 1012
vector genomes [VG]/kg body weight) led to transient factor
IX expression; however, asymptomatic liver inflammation
ensued, with loss of the successfully gene-transduced hepa-
tocytes.2 Subsequent investigation suggested that challenge
with recombinant AAV vectors can, in a vector capsid dose-
dependent fashion, lead to reactivation of memory T and B
cell responses in an individual who has been exposed to wild-
type AAV earlier in life. The reactivation of this adaptive
immune response appears capable of inciting a cytotoxic T
lymphocyte (CTL)-mediated elimination of the hepatocytes
that have processed the recombinant virus vector and that
present AAV capsid epitopes for immune recognition.3 In
light of these findings, our group and other research groups
pursued strategies to increase the efficiency of AAV factor IX
gene delivery in hopes of achieving clinically meaningful
expression while limiting vector doses to levels that are lower
than the doses associated with apparent CTL-mediated im-
mune response.4–6
A clinical trial sponsored by St. Jude Children’s Research
Hospital and conducted at the University College of London
(SJCRH/UCL) achieved the first unequivocal clinical success
for hemophilia gene therapy. Persistent expression of 1–6%
normal factor IX activity was demonstrated in all six indi-
viduals receiving the ‘‘scAAV2/8-LP1-hFIXco’’ vector.7 The
advances incorporated into the SJCRH/UCL vector included
(1) the use of a self-complementary rather than single-
stranded AAV genome form; (2) codon optimization of the
factor IX sequence; and (3) use of the capsid from AAV8 (a
rhesus macaque serotype) rather than AAV2 (for which
humans are the natural host), associated with improved liver
tropism and allowing (4) peripheral venous rather than direct
intraportal venous vector infusion. In this SJCRH/UCL trial,
evidence of capsid dose-dependent immune hepatitis was
observed once again after escalation to a dose of 2 · 1012
VG/kg body weight. The persistence of factor IX expression
despite immune targeting of the vector-transduced hepato-
cytes was credited by these investigators to the institution of
immune suppression with a course of corticosteroids in most
individuals treated at this highest vector dose. Of note is that
the production methods used to generate the clinical vector
resulted in vector stocks that contained at least 80% empty
AAV capsids,8 so that the dose of 2 · 1012 VG/kg was as-
sociated with an exposure to at least 1 · 1013 potentially
immunogenic AAV capsids per kilogram.
Gain-of-function variants of factor IX carrying a single
amino acid change at amino acid 338 have been de-
scribed,9,10 as well as their incorporation into gene therapy
vectors for preclinical applications in vivo.11–15 An AAV
vector that incorporates the improvements employed in the
SJCRH/UCL factor IX vector and in addition directs the
expression of a gain-of-function FIXR338L variant is cur-
rently undergoing evaluation in a phase 1/2 clinical trial for
hemophilia B, and its preclinical evaluation is described
herein (www.clinicaltrials.gov/show/NCT01687608). These
investigations suggest that scAAV8.FIXR338L vector (now
being tested in a human clinical trial by Baxter Healthcare
[Deerfield, IL] and labeled BAX335) has the potential to
achieve clinically meaningful circulating factor IX activity
without relying on exposure to doses of vector capsid that
have been associated in previous trials with hepatic in-
flammation and rescue immunosuppression.
Materials and Methods
AAV vector production
The construct pTTRhFIXopt, which directs the expression
of a codon-optimized wild-type human factor IX (FIX) se-
quence from a liver-specific transthyretin (TTR) promoter,
has been described previously.6 A QuikChange site-directed
mutagenesis kit (Agilent Technologies, Santa Clara, CA) was
used to generate single nucleotide changes in this expression
cassette, resulting in the cassettes encoding alanine (FIX-
R338A), leucine (FIXR338L), or glutamine (FIXR338Q).
The FIX expression cassettes were subsequently tested for
expression after packaging in self-complementing AAV
vectors.
In separate experiments, the sequence of the LP1 promoter/
enhancer/SV40 intron from the scAAV2/8-LP1hFIXco con-
struct was synthesized and substituted in the FIXR338L ex-
pression cassette so as to create an expression cassette to
compare the effect of transcriptional regulatory elements in the
scAAV2/8-LP1-hFIXco vector and the scAAV8.FIXR338L
vector16 while maintaining all the FIX transgene and AAV
backbone elements identical between the vectors. All recom-
binant AAV8 vectors were produced at the University of North
Carolina at Chapel Hill Vector Core Facility, using a triple
transfection protocol as previously described.17 Suspension
HEK293 cells were grown in the WAVE bioreactor system
(GE Healthcare, Piscataway, NJ) to produce Good Manu-
facturing Practice (GMP) vector, using a manufacturing pro-
cess that is both scalable and animal component free.
Animal care and use
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee of the University of
North Carolina at Chapel Hill. All animal experiments were
performed in hemophilia B (FIX–/–) mice maintained in a
C57BL/6 strain background,18 or hemostatically normal
C57BL/6 mice ( Jackson Laboratories, Bar Harbor, ME) as
noted. Adult male hemophilia B mice were injected with the
indicated doses of AAV vector via the tail vein (for pe-
ripheral intravenous delivery) or via open abdominal sur-
gery with direct visualization and infusion of the superior
mesenteric vein (for portal vein delivery). Mice were 7–10
weeks of age, weighing 20–25 g at the time of experiments,
and experimental groups were matched for age and weight.
Portal vein and tail vein administration,6 tail transection
bleeding challenge,19 and joint capsular puncture bleeding
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challenge were performed as described previously.20,21
Blood for all studies was collected from the retroorbital
venous plexus under anesthesia using isoflurane as previ-
ously described,21 with the exception of blood for thrombin–
antithrombin (TAT) evaluation, which was obtained under
anesthesia from an open puncture of the inferior vena cava,
performed as a terminal procedure.
Human factor IX antigen, activity, and antibody assays
and thrombin/antithrombin III assay
The human factor IX antigen, one-stage human factor IX
activity, human factor IX-directed IgG, and human factor IX
Bethesda inhibitor assays were performed as previously
described and are specific for human factor IX (although
not specifically standardized for factor IX variants, e.g.,
FIXR338L).21,22 The specific activity of factor IX expressed
as units of factor IX activity per milligram of protein (U/mg)
was calculated by dividing the factor IX activity (U/ml) by
the concentration of the factor IX protein (factor IX antigen)
(mg/ml). TAT complexes were measured from platelet-poor
citrated plasma collected as a terminal puncture of the
inferior vena cava 4 weeks after factor IX vector adminis-
tration, using an Enzygnost TAT micro ELISA system
(Siemens Healthcare Diagnostics, Tarrytown, NY).
Histopathological examination at necropsy
of hemophilic mice after AAV8-mediated expression
of wild-type human factor IX and FIXR338L
At the time of terminal sacrifice of hemophilic mice after
expression of either transgenic human WTFIX or human
FIXR338L from AAV vectors, mice were killed by CO2 as-
phyxiation for histopathological examination. Mice were
examined at time of necropsy for gross signs of hemorrhage
and all tissues were immersion-fixed in either Bouin’s fixative
(RICCA Chemical, Arlington, TX) or 10% neutral buffered
formalin, trimmed, processed, sectioned, and stained with
hematoxylin and eosin (H&E) by routine methods, and a
panel of 18 organs and tissues was evaluated microscopically
for histopathological changes (C.J.B., blinded to experi-
mental manipulation). Heart, lung, liver, spleen, kidney, and
brain were evaluated for the presence of fibrosis and/or mi-
crovascular thrombus formation by immunohistochemistry
for fibrinogen, using AB34 from Abcam (Cambridge, MA),
and additional evaluation with Masson’s trichrome (collagen
stains blue, muscle red) and phosphotungstic acid hematox-
ylin (PTAH), which stains collagen pink but fibrin and muscle
blue.
Effect of empty capsids on AAV8 transduction
in the presence of AAV8-neutralizing antibodies
To evaluate whether empty AAV8 capsids in the therapeutic
vector preparation exert any positive or negative effect on
scAAV8.FIXR338L transduction in vivo (especially in the
presence of AAV8 neutralizing antibodies [NAbs]), anti-
AAV8 NAbs were generated. C57BL/6 mice were vaccinated
with an AAV8 vector expressing an irrelevant transgene (a1-
antitrypsin, A1AT). The humoral immune response was
boosted with an additional AAV8.A1AT intraperitoneal in-
jection. Two weeks later, serum was collected and pooled. The
AAV8 neutralizing titer of the serum was determined by ex-
amining the ability of serial dilutions of serum to abrogate the
transduction of RC32 cells in tissue culture by an AAV8.GFP
vector, as previously described.23 Empty rAAV capsids, a gift
from M. Agbandje-McKenna (Department of Biochemistry
and Molecular Biology, University of Florida, Gainesville, FL)
were generated by a triple transfection protocol and CsCl gra-
dient ultracentrifugation collection, as previously described.24
NAb was passively transferred to FIX–/– mice by tail vein in-
jection, achieving a circulating AAV NAb titer of either 1:16
(moderate titer) or 1:2 (near the lower limit of detection). Mice
were then treated via the tail vein with either scAAV8
.FIXR338L cGMP-grade vector or a combination of scAAV8
.FIXR338L and empty AAV8 particles at the ratios detailed in
Table 3 and described in Results.
Pivotal Good Laboratory Practice toxicology
and biodistribution study in hemostatically normal mice
An 18-week toxicity and biodistribution study of Good
Laboratory Practice (GLP) scAAV8.FIXR338L vector was
performed in normal male C57BL/6 mice (having normal he-
mostasis at baseline). The study design is shown in Supple-
mentary Table S1 (supplementary data are available online at
www.liebertpub.com/hum). Briefly, scAAV8.FIXR338L vec-
tor at a ‘‘therapeutic dose’’ and at a ‘‘supraphysiological dose’’
were compared with vehicle (5% sorbitol in 350 mM NaCl) after
tail vein administration to adult mice (n = 60 mice per group).
The lower dose of 4 · 1011 VG/kg was based on the cumulative
results of the expression studies performed in FIX–/– mice
showing that this ‘‘therapeutic dose’’ resulted in > 50–100%
normal human factor IX activity 40–42 weeks after a single
delivery. A 10 times higher dose of 4 · 1012 VG/kg was studied
as a ‘‘supraphysiological dose.’’ At each of four time points after
vector delivery (day 3, week 3, week 10, and week 18) 15 mice
from each dose group were killed and the following evaluations
were completed: blood for complete blood cell counts and
morphology, clinical chemistry panel; factor IX antigen, ac-
tivity and factor IX Bethesda inhibitor; anti-AAV8 IgG, anti-
FIX IgG1 (weeks 10 and 18 only); and complete necropsy with
gross and microscopic evaluation of 27 tissues along with DNA
isolation and PCR analysis for vector biodistribution. After this
multitissue examination, the heart, lungs, kidneys, brain, liver,
and spleen were independently examined for the presence of
fibrosis and/or thrombus formation as described previously
(C.J.B., blinded to experimental design). Additional histopath-
ological examination included screening of livers for CD8 + T
cells and evaluation of splenocytes for interferon-c enzyme-
linked immunospot (ELISPOT) immune response to AAV8 and
FIXR338L protein.25
Statistical methods
Quantitative data are presented as means – SD. The Stu-
dent t test was used to perform all statistical analyses. P
values less than 0.05 were considered a statistically signif-
icant difference.
Results
Relative expression of gain-of-function factor
IX variants in hemophilic mice using AAV vectors
Single amino acid substitutions for Arg-338 in the factor
IX catalytic domain with alanine (FIXR338A), glutamine
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(FIXR338Q), and leucine (FIXR338L) have each been ob-
served to produce a factor IX variant with increased specific
activity.9,10,15 We examined the relative potential advantage
of each of these variants for augmenting the clotting activity
of factor IX. Each of these substitutions was generated in
otherwise identical liver-directed codon-optimized factor IX
AAV vectors and injected via the tail vein into hemophilia
B mice. The mice were monitored for 29 weeks, and
throughout the period of observation each of the variants
demonstrated a specific activity that exceeded the expected
wild-type factor IX specific activity of *200 U/mg protein
(Supplementary Fig. S1A and B). On average, FIXR338L
gave the greatest advantage in terms of the specific activity
of the expressed proteins and resulted in plasma factor IX
activity that was approximately two times higher than the
FIXR338A and FIXR338Q variants throughout the 29
weeks of observation. Further vector development incor-
porated the FIXR338L variant as described below.
Expression of WTFIX and FIXR338L from AAV
in mice: long-term in vivo expression results
Self-complementary AAV8 vector was generated on the
basis of the pTTRhFIXopt expression cassette and expressed
the codon-optimized wild-type factor IX cDNA (WTFIX
vector). An additional vector, scAAV8.FIXR338L, was gen-
erated with identical features except for a single nucleotide
change in the factor IX cDNA resulting in the expression of the
FIXR338L variant. Each vector was delivered into the portal
venous circulation of adult C57BL/6 FIX–/– mice (n = 6 mice
per group) at a dose of 4 · 1011 VG/kg and in vivo expression of
factor IX antigen (protein) and activity were assayed during 42
weeks of observation. Plasma factor IX protein expression was
consistently at least two times higher from the WTFIX vector
than the FIXR338L vector (Fig. 1A). The mechanism ex-
plaining the mildly lower FIX protein expression from the
FIXR338L vector is under investigation. Nevertheless, plasma
factor IX activity in the FIXR338L cohort was three to four
times higher than in the WTFIX cohort throughout the 42
weeks (Fig. 1B). The improved factor IX activity mediated by
scAAV8.FIXR338L reflects the finding that the WTFIX vector
led to plasma factor IX specific activity that was close to the
expected specific activity of human FIX (200 U/mg), whereas
the scAAV8.FIXR338L vector generated more than six times
higher specific activity of the expressed FIXR338L protein
throughout the period of observation (Fig. 1C). Before sacrifice
at 42 weeks postinjection, all mice underwent a tail vein tran-
section bleeding challenge to assess in vivo function of the
vector-expressed human factor IX. Untreated hemophilia B
mice had prolonged and profuse bleeding with this challenge
FIG. 1. Expression in plasma of wild-type factor IX and FIXR338L from otherwise identical liver-directed expression
cassettes in FIX–/– mice. Codon optimization of the factor IX cDNA used in each vector was identical. The Leu-338 variant
results from a single nucleotide substitution in the codon-optimized FIX cDNA. The number of C57BL/6 FIX–/– mice that
received intraportal venous vector was 13 in the scAAV8.WTFIX treatment group (WTFIX) and 10 in the scAAV8
.FIXR338L group. (A) Total human factor IX protein expressed. (B) Specific activity of circulating factor IX. The normal
specific activity of recombinant factor IX is *200 U/mg. (C) Circulating factor IX activity as assayed in a one-stage
clotting assay (factor IX-specific activated partial thromboplastin time) demonstrated sustained FIXR338L expression at
supraphysiological levels for most of the 40 weeks of observation. (D) At the end of the follow-up, plasma factor IX activity
was measured and then transection of the tail tip was performed at a uniform circumference of 1.5 mm. After this bleeding
challenge, hemophilia B mice (FIX–/–) experienced severe bleeding, which resulted in diminished activity or distress
requiring euthanasia of 8 of 14 mice. All mice that had received either factor IX gene therapy vector as a single injection
40 weeks earlier survived the tail transection and remained active, similar to the hemostatically normal mice (WT) that
underwent the same bleeding challenge.
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and the majority died or became moribund and required eu-
thanasia during 8 hr of observation after this bleeding chal-
lenge. Mice that received portal vein delivery of either vector
survived the tail transection and were active and drinking/
feeding normally throughout 8 hr of observation, similar to
hemostatically normal control mice that experienced the same
bleeding challenge (Fig. 1D). Peak expression from scAAV8.
FIXR338L ranged from 300 to 400% normal human factor
IX (hFIX) activity, and long-term expression plateaued
above *125% normal hFIX activity (Fig. 1B). Peak ex-
pression from the WTFIX vector was in the range of 60–80%
normal, and long-term expression plateaued above *30–
60% normal human factor IX activity. Mice from both
groups were killed at *1 year of age and full histopatho-
logical examination was performed. No microangiopathic or
macroangiopathic thrombi were found on examination of
lung, liver, brain, kidney, heart, or spleen of hemophilic mice
expressing either physiological levels of wild-type human
factor IX or physiological or supraphysiological levels of
human FIXR338L.
Liver-directed AAV vector:
comparison of transcriptional regulatory elements
We previously reported our effort to identify compact yet
strong regulatory elements to direct factor IX gene expres-
sion in the liver from self-complementing AAV vectors.6 A
similar effort reported by Nathwani and colleagues led to the
development of the scAAV2/8-LP1-hFIXco vector used in
the SJCRH/UCL human clinical trial.16 Once we established
the potential of the FIXR338L transgene to incrementally
improve plasma factor IX activity compared with wild-type
FIX, we next examined the relative influence of the ex-
pression elements (exclusive of the transgene choice) in the
scAAV8.FIXR338L vector compared with the clinically
tested SJCRH/UCL scAAV2/8-LP1-hFIXco vector. Hemo-
philic mice received a 4 · 1011 VG/kg concentration of
either scAAV8.FIXR338L or a vector expressing the iden-
tical codon-optimized FIXR338L sequence from the LP1
promoter/enhancer/SV40 intron from the SJCRH vector,
and the plasma expression of factor IX activity was mea-
sured serially over 40 weeks of observation. No consistent
advantage in FIXR338L expression from either expression
vector was observed (see Supplementary Fig. S2A). This
finding also held true regarding correction of the bleeding
phenotype. Mice receiving either vector expressed approx-
imately 50% circulating factor IX activity 40 weeks after
vector delivery (as recorded in Supplementary Fig. S2A)
and demonstrated protection that was comparable to he-
mostatically normal mice when challenged by tail vein
transection at this time point (Supplementary Fig. S2B).
Dose–response study of intravenously administered
scAAV8.FIXR338L
AAV serotype 8 demonstrates high tropism for liver. The
feasibility of liver-directed gene therapy for hemophilia
using peripheral intravenous rather than intra-portal venous
delivery has been demonstrated in human clinical trials4,7
and is a less invasive approach for individuals with hemo-
philia, who have an increased risk of bleeding from catheter-
directed intrahepatic gene delivery. A range of intravenous
doses of scAAV8.FIXR338L from 1.0 · 1010 VG/kg to
4 · 1012 VG/kg were tested, resulting in plasma factor IX
protein levels that ranged from undetectable up to supra-
physiological levels (Fig. 2A). At any given dose across
this wide range, the specific activity of the expressed factor
IX was five to eight times normal and was sustained for
months. As an example, a vector dose of 4 · 1011 VG/kg
yielded plasma factor IX protein levels of 9–10% resulting
in 55–65% activity in the human factor IX activity assay
(Fig. 2A and B). The increased specific activity of the
transgenic FIXR338L protein was also reflected in the
observation that for the lowest dose cohort (1.0 · 1010 VG/
kg), by the second week half of the animals had plasma
factor IX activity > 1%, despite the fact that no circulating
factor IX antigen could be detected at the level of sensi-
tivity of the assay (*10 ng/ml, which is equivalent to
*0.2% normal protein level) (Fig. 2B). An additional
cohort of mice received scAAV8.FIXR338L at 4 · 1011
VG/kg via the portal vein route to allow direct comparison
of R338LFIX expression via portal vein and intravenous
delivery. Over the 32 weeks of expression there was no
consistent difference in plasma factor IX expression
achieved by either the portal vein or intravenous route,
confirming previous reports.
After euthanasia after tail transection challenge (see
below), pathology of the heart, lungs, kidneys, brain, liver,
spleen, representative skeletal muscle, and mesenteric
lymph node was examined by microscopy from the two
highest dose cohorts (8 · 1011 and 4 · 1012 VG/kg). Age-
matched FIX–/– mice were included as controls. No micro-
or macrovascular thrombosis, fibrosis, fibrin depositions, or
organ pathology attributable to scAAV8.FIXR338L treat-
ment was present.
Dose-dependent protection from hemorrhage
in tail transection challenge
After 32 weeks of expression, all mice in the tail vein
dose–response study underwent tail vein transection to eval-
uate the hemostatic potential of the expressed FIXR338L
(Fig. 2C). At the time of tail vein transection, the cohort of
mice that received the lowest dose of scAAV8.FIXR338L did
not have measurable plasma factor IX activity and all other
doses led to some plasma factor IX expression (the mean
factor IX activity for each cohort is recorded in Fig. 2C). The
lowest vector dose associated with partial protection from
blood loss was 5 · 1010 VG/kg (at *3.6% mean circulating
FIX activity); however, three of eight mice at this dose
showed hemorrhage similar to or worse than that of saline-
treated hemophilic mice. A dose response of increasing
protection from blood loss was demonstrated as the dose
escalated ( p < 0.01 for doses 1.5 · 1011 VG/kg and above
when compared with saline-treated FIX–/– mice). At the dose
of 1.5 · 1011 VG/kg every mouse was protected from blood
loss.
Dose-dependent protection from the development
of hemarthrosis and bleeding-induced joint pathology
The tail transection bleeding challenge measures hemo-
static protection from an exsanguinating wound. In the
clinical care of hemophilia, the most common location of
bleeding is into musculoskeletal sites, with recurrent joint
hemorrhage causing the blood-induced joint deterioration
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(hemophilic arthropathy) that is the most common compli-
cation of hemophilia. Our group and others have used a
model of induced recurrent joint hemorrhage to study he-
marthropathy.20,21,26 The joint bleeding challenge consists
of a puncture of the knee joint capsule, using a small-gauge
needle. The histopathological features of hemophilic syno-
vitis that ensue in hemophilic mice after this bleeding
challenge can be quantified by a murine hemophilic syno-
vitis grading system validated in the Valentino laboratory.27
The system has a 0-to-10 point scale that quantitates in-
creasing evidence of hyperplasia of the synovial lining cells
and of increased synovial vasculature replacing the sub-
synovial space, as well as the presence of hemosiderin iron
staining, frank blood and cartilage erosion, or synovial
FIG. 2. Dose response after
scAAV8.FIXR338L vector
was delivered by peripheral
(tail) vein. FIX–/– mice (six to
eight per group) received the
indicated doses of scAAV8
.FIXR338L as a single tail vein
injection to model the periph-
eral venous route of dosing
planned for human clinical ap-
plication. So as to allow com-
parison of tail vein (TV) and
portal vein (PV) administration
using the same vector dosing
examined in Fig. 1, separate
groups of age-, weight-, and
sex-matched FIX–/– mice re-
ceived 4.0 · 1011 VG/kg by PV,
with factor IX expression dis-
played by the green triangles.
(A) Circulating factor IX pro-
tein. (B) Circulating factor IX
activity. At any given dose, the
specific activity of plasma fac-
tor IX (factor IX activity/factor
IX antigen, expressed in units/
mg protein) was five to eight
times normal, with factor IX
expression persisting over
months. Plasma was examined
at each time point for the de-
velopment of antibodies di-
rected against factor IX. No
factor IX inhibitors (as measured
by Bethesda assay) or anti-FIX
IgG (as measured by ELISA)
was detected in any animal
throughout the observation. (C)
Dose-dependent protection from
hemorrhage in the tail transec-
tion bleeding challenge. At 32
weeks after vector delivery, all
mice from each dose group had
plasma factor IX activity deter-
mined (as recorded on the x axis
below each column) and then
underwent a tail transection
bleeding challenge and the
amount of blood loss in 10 min
after wounding was collected
and quantitated by measuring
the optical density (OD) of the
shed hemoglobin.
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villous formation. This model is useful for examining the
potentially protective effects of new therapeutic approaches,
because the pathology that develops after this injury clearly
distinguishes hemophilic mice from control mice with intact
hemostasis. When the joint pathology is graded 2 weeks
after injury, hemostatically normal mice exposed to this
injury essentially never develop synovitis, with 100% of
mice scoring less than 2 on the Valentino synovitis grade
(historic mean, 0.14).21 Untreated hemophilic mice essen-
tially never score less than this threshold of 2 points out of
10, whereas the historic mean is *4.4 out of 10 for he-
mophilic mice.
Separate groups of FIX–/– mice were treated intrave-
nously with scAAV8.FIXR338L or the corresponding vector
expressing WTFIX at a variety of doses to determine whe-
ther the expression of AAV.FIX preserves the health of
hemophilic joints. At 4 weeks after vector administration,
factor IX activity in the plasma was recorded and animals
received a single induced joint hemorrhage; joints were
collected 2 weeks later to grade the degree of synovitis that
developed, using the Valentino grading system (Fig. 3).
Mice given the lowest dose (2 · 1010 VG/kg) of WTFIX
vector (n = 6) expressed factor IX activity between 0.8 and
1.4% of normal human factor IX activity in plasma (see
scatterplot in Fig. 3A). In contrast, mice given the same dose
of scAAV8.FIXR338L (n = 6) expressed 1.7–6.2% activity.
Most importantly, this expression correlated with relative
protection from synovitis. Five of six mice receiving the
scAAV8.FIXR338L vector at the low dose displayed sig-
nificant protection, with scores approaching the threshold
score of 2 that separates hemophilic mice from non-
hemophilic mice. At the highest dose of 2 · 1011 VG/kg, the
clinically relevant joint protection was more obvious. Mice
that received scAAV8.FIXR338L (n = 7), but not mice re-
ceiving WTFIX vector (n = 5), expressed 57–120% factor IX
and six of seven mice demonstrated joint protection with
histopathological features that did not differ from those of
injured hemostatically normal wild-type mice.
Detection of factor IX antibodies in hemophilia B mice
after scAAV8.FIXR338L administration
The development of an antibody response directed against
replacement factor IX that neutralizes its procoagulant ac-
tion (an ‘‘inhibitor’’) is an unusual but potentially morbid
complication of the treatment of hemophilia B. Develop-
ment of inhibitors occurs in about 2–4% of patients with
severe hemophilia B. Mice that received gene therapy vector
in each of the studies described here were screened at
multiple time points for the development of antibodies that
interfere with the activity of normal factor IX in an assay of
coagulation function (Bethesda inhibitor assay); in addition,
at the time of euthanasia the mice were tested for IgG that
bound factor IX specifically by ELISA. The results of all
antibody studies in the preclinical program are included in
Table 1. Also included in Table 1 (assessed by FIX Be-
thesda assay only) are mice that received AAV vectors and
expressed WTFIX or FIXR338L after vector delivery di-
rectly into the intraarticular space of the knee joint, fol-
lowing a protocol we have reported previously.21 The
intraarticularly treated mice add to our experience with
expression of the scAAV8.FIXR338L vector in immuno-
competent mice (C57BL/6 strain, expressing HLA mouse
H2b haplotype). In this total experience in over 200 mice,
including 168 with a factor IX null phenotype, a single
factor IX inhibitor antibody has been observed. This arose in
a factor IX null mouse whose first exposure to human factor
IX was in the context of portal venous vector delivery, ac-
complished via open abdominal surgery that involves re-
flection of the intestines out of the abdominal cavity. This
factor IX inhibitor was present at a clinically low titer of < 1
unit in the factor IX Bethesda assay and a concentration of
0.1 lg/ml IgG; each of these values is at the lower level of
sensitivity of the assay.
Thrombin–antithrombin complex formation
In addition to the necropsy evaluations for evidence of
thrombosis, the potential for FIXR338L expression to lead to
inappropriate activation of coagulation was assessed by
measuring plasma TAT complexes. Adult FIX–/– mice re-
ceived a 2 · 1012 VG/kg concentration of vector expressing
either WTFIX or FIXR338L, whereas control mice were in-
jected with normal saline. Four weeks later, plasma was
collected via a single, open terminal puncture of the inferior
vena cava. Plasma factor IX activity was determined by a
one-stage factor IX activity assay and TAT complexes were
measured in an ELISA that has been previously shown to
detect mouse TATs (Enzygnost; Siemens Healthcare Diag-
nostics). As shown in Table 2, scAAV8.FIXR338L expres-
sion of FIXR338L at physiological or supraphysiological
levels was not associated with elevations in TAT levels when
compared with expression of WTFIX, and was not associated
with absolute elevations of TAT.
Empty vector particles do not circumvent
the neutralization of factor IX gene delivery
by AAV-neutralizing antibodies
The rAAV8 preparation used in the SJCRH/UCL gene
therapy trial contained at least four or five empty capsids,
containing no F9 transgene, for each potentially therapeutic
F9-containing AAV vector (80–90% empty capsids).8 Our
strategy to pursue higher factor IX expression using the
FIXR338L and vector stocks with minimal empty capsid
is premised on the concept that diminishing the exposure
to potentially immunogenic empty capsids may increase
rAAV8.F9 safety. Nonetheless, it is conceivable that the
presence of empty rAAV capsids might have contributed in
some way to the successful gene expression in the SJCRH/
UCL trial. For example, some investigators have suggested
that empty capsids could serve as a ‘‘decoy’’ for circulating
AAV-neutralizing antibodies (AAV NAbs), thereby aiding
transduction by the transgene-containing vectors in indi-
viduals with Nabs.28 To model the scenario that existed in
the SJCRH/UCL trial, we used well-characterized empty
AAV8 capsids obtained as a kind gift of M. Agbandje-
McKenna. We generated anti-AAV8 NAbs by vaccinating
C57BL/6 mice with an AAV8 vector. Serum was collected
and pooled, and the AAV8-NAb titer was defined. cGMP-
grade scAAV8.FIXR338L, the fully characterized AAV8.F9
vector used in an ongoing human clinical trial, was exam-
ined by electron microscopy (EM) and found to contain
< 10% empty capsids (Fig. 4). NAb was passively trans-
ferred to FIX–/– mice by tail vein injection, achieving a
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FIG. 3. Dose-dependent protection from the development of hemarthrosis and bleeding-induced joint pathology is improved
by the substitution of FIXR338L. FIX–/– mice were treated via the tail vein with scAAV8.FIXR338L (squares) or the
corresponding vector expressing WTFIX ( · ). Four weeks after vector delivery, the mice received a unilateral right hindlimb
knee joint needle puncture to induce hemarthrosis. Two weeks after injury, knee joints were collected and scored for synovitis,
using the Valentino mouse synovitis score. (A) At both the lower dose of 2 · 1010 VG/kg (left) and the higher dose of 2 · 1011
VG/kg (right), the expression from scAAV8.FIXR338L (squares) results in higher plasma levels of factor IX activity when
compared with the WTFIX vector ( · ). The average synovitis score of 4.4 was previously reported for a large cohort of
untreated FIX–/– mice that underwent this bleeding challenge, and this value is represented by the dashed line. A large group
of strain-matched hemostatically normal C57BL/6 mice exposed to this bleeding challenge developed a mean synovitis score
of 0.14, with a range of 0–2.0 (demarcated by the shaded rectangle). (B) Representative histopathology of knee joints 2 weeks
after single knee joint puncture injury. The area bounded by the black rectangle in each top panel (original magnification,
· 40) is shown at an original magnification of · 200 in the immediately underlying bottom panel. Normal joint anatomy was
preserved in hemostatically normal C57BL/6 wild-type control mice (left) by an open joint space (*), thin flat synovial
epithelial cells (arrowhead) supported by an unremarkable fatty and fibrovascular stroma, and subsynovial fat pad (**)
composed predominantly of scant small blood vessels (arrows) (bottom left). In contrast, FIX–/– mice given scAAV8
.FIXR338L (2 · 1010 VG/kg) that expressed FIXR338L (middle) demonstrated minimal to mild changes of synovitis (synovitis
score, *2/10); an increase in the size and number of blood vessels (neovascularization) (arrows) in the subsynovial fat pad
(**) is present; however, there is little to no increase in synovial epithelial cell thickness (arrowhead). Mice given WTFIX
vector (2 · 1010 VG/kg) had severe synovitis (synovitis score, > 4/10) (right) with a marked increase in synovial thickness in
concert with effacement and replacement of the subsynovial fat (**) pad by proliferation of synovial epithelial cells and
granulation tissue, admixed with inflammatory cells. As observed in clinically severe hemarthrosis, we see pannus formation
(P) when these proliferating cells grow over the articular cartilage, resulting in erosion (*) in combination with marked
neovascularization (arrows), and foci of fibrinonecrotic debris (D). Hematoxylin–eosin. Scale bars, 200 lm.
76 MONAHAN ET AL.
circulating AAV NAb titer of either 1:16 (moderate titer) or
1:2 (near the lower limit of detection) (Table 3). Mice were
treated next with one of the following: either 1 · 1011 VG/kg
of scAAV8.FIXR338L ( < 10% empty AAV capsids); or
with 1 · 1011 VG/kg scAAV8.FIXR338L plus 1 · 1011 VG/
kg rAAV8 empty capsids (*50% empty capsids); or with
1 · 1011 VG/kg scAAV8.FIXR338L plus 4 · 1011 VG/kg
rAAV8 empty capsids (*80% empty capsids). A group of
mice received no NAb and were treated with scAAV8
.FIXR338L at 1 · 1011 VG/kg to be a positive control for F9
gene delivery. In the absence of NAb, mean plasma factor IX
activity after intravenous scAAV8.FIXR338L was 7.4 and
6.7% at 2 and 4 weeks, respectively. Passively transferred
NAb at either 1:2 or 1:16 titer prevented transgene expression
(FIX activity < 1%, lower limit of sensitivity). If the NAb
titer was measurable, then AAV8 neutralization was not ab-
rogated by the presence of empty capsids at either the lower
dose of empty capsid or the dose that yielded a large excess
of empty capsids (expression of FIX activity < 1%).
Pivotal GLP toxicology and biodistribution study
in hemostatically normal mice
Plasma FIX activity was measured at all time points, using a
one-stage clotting assay, and was expected to measure the an-
imal’s baseline normal hemostatic activity (i.e., the baseline
activity that results from endogenous mouse factor IX) as well
as functional human factor IX expression from the scAAV8
.FIXR338L vector. The values reported represent the factor IX
activity above mouse factor IX baseline (at each time point
correcting for the amount of activity measured in the vehicle-
treated group). The mean FIX activity in the 4 · 1011 VG/kg
dose group peaked at *200%, subsequently decreasing to a
mean of *50% above baseline at the 18-week point. The
activity in the 4 · 1012 VG/kg dose group was maintai-
ned throughout the study at greatly supraphysiological levels
( > 1200%) (Supplementary Fig. S3). No factor IX-binding IgG
antibodies or factor IX Bethesda inhibitors developed in any
animals and there were no differences in blood hematology or
clinical chemistry parameters between control and scAAV8
.FIXR338L-treated mice. One animal in the lower vector dose
group, having no prior signs of toxicity, died on study at day 67
and postmortem examination revealed only chronic changes of
mild myocardial fibrosis that were not believed to be large
enough to be the direct cause of death. One animal in the high-
dose group (supraphysiological FIX expression) died on day 99
with no significant macro- or microscopic abnormalities on
postmortem examination. The complete histopathological
analysis of all vector-treated mice and saline-treated control
mice was unremarkable with the exception of mild focal he-
patic necrosis in two of five mice in the high-dose group at the
week 10 time point only. The foci were small and serum
chemistries for liver enzymes were normal (data not shown).
Minimal focal liver necrosis was also noted in control and
vector-treated mice at a similar frequency across the groups.
Evaluation of livers for CD8 + T cells was negative; thus evi-
dence of cellular immune response to scAAV8.FIXR338L
treatment was excluded. Consistent with this finding were re-
sults of splenocyte interferon-c ELISPOT analyses, in which
we found only low and transient T cell stimulation to the AAV8
capsid and no T cell response to the factor IX transgene (S.W.J.
McPhee and R. Calcedo, data not shown).
Consistent with the known hepatic tropism of AAV8,
biodistribution analysis after peripheral intravenous delivery
showed the highest concentration was in the liver, the con-
centration was dose-related, and was highest at the earliest
Table 1. Factor IX Antibody Formation After scAAV8 Treatment Expressing
Either Wild-Type FIX or FIXR338L














WT C57BL/6 Peripheral vein FIXR338L 0/40 — 0/20 ND
FIX–/– C57BL/6 Peripheral vein WTFIX 0/15 — 0/15 ND
FIXR338L 0/88 — 0/88 ND
FIX–/– C57BL/6 Intraportal vein WTFIX 0/49 — 0/49 ND
FIXR338L 1/40 < 1 1/40 0.04–0.12
FIX–/– C57BL/6 Intraarticular WTFIX 0/72 — 0/72 NP
FIXR338L 0/40 — 0/40 NP
BIU, Bethesda inhibitor units; FIX–/–, factor IX knockout mice; ND, none detected; NP, not performed; WT, wild type.
Table 2. Plasma Thrombin–Antithrombin Complexes: A Marker of Activation of Coagulation
After scAAV8FIX Gene Therapy in Hemophilia B Mice
Transgene Dose (VG/kg) n Human FIX antigen (lg/ml) Human FIX activity (%) TAT (ng/ml)
Untreated Normal saline 6 — < 1 31.7 – 18.3
WTFIX 1.2 · 1012 6 4.17 – 1.96 85.6 – 26.6 27.7 – 18.8
FIXR338L 6 · 1011 7 0.83 – 0.34 90.7 – 35.4 23.0 – 12.5
FIXR338L 2 · 1012 6 3.42 – 1.07 340.0 – 122.6 25.9 – 13.1
FIX, factor IX knockout; TAT, thrombin–antithrombin; VG, vector genomes.
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time point (3 days). Full biodistribution data of the detected
scAAV8.FIXR338L sequence at each time point in nine
organs/tissues (liver, spleen, heart, skeletal muscle, ingui-
nal lymph node, kidney, lung, brain, testis) are included in
Supplementary Table S2. On examining the groups exposed
to the higher vector dose (see Supplementary Table S2 and
Supplementary Fig. S4), on day 3 the organ with the next
highest tissue concentration relative to the liver was the
spleen (27-fold lower vector copies; i.e., 4.29 · 106 copies in
the liver and 1.58 · 105 copies in the spleen). The spleen had
either the highest or second highest extrahepatic distribution
of vector at the day 3 and week 3 time points, using either the
lower or higher dose. By week 10, however, vector distri-
bution in the spleen decreased to less than 1% of the vector
copy number measured on day 3, and was *500- to 600-fold
lower than in the liver. At week 3 the extrahepatic concen-
tration of vector in the higher vector dose group was highest
in the heart (118-fold lower than in liver). In contrast to the
FIG. 4. Manufacture of GLP vector produced from scalable suspension cell culture eliminates most contaminating empty
AAV capsids. Left: Transmission electron micrograph of the clinical vector used in the dose–response and toxicity/biodis-
tribution studies, demonstrating a favorable ratio of therapeutic particles to defective interfering particles (empty capsids make
up less than 10% of vector stock). Black circles are superimposed to show examples of the relatively hollow appearance that is
typical of empty vector capsids. Right: Silver stain of clinical vector demonstrates only three proteins, corresponding to the
AAV structural proteins Vp1, Vp2, and Vp3, present at the expected ratio of *1:1:9. Lanes 2 and 4 contain identical vector.
Table 3. Effect of AAV8 Neutralizing Antibodies on In Vivo Transduction by scAAV8.FIXR338L
and Failure of Excess Empty AAV8 Capsids to Affect Transduction







(EC) (VG/kg) Week 1 Week 2 Week 4 Week 8
Vector alone None 1 · 1011 None 5.6 – 0.8 8.2 – 2.9 7.5 – 2.1 7.9 – 2.0
Moderate-titer NAb 1:16 1 · 1011 None < 1 < 1 < 1 < 1
Moderate-titer NAb + 50% EC 1:16 1 · 1011 1 · 1011 < 1 < 1 < 1 < 1
Moderate-titer NAb + 80% EC 1:16 1 · 1011 4 · 1011 < 1 < 1 < 1 < 1
Week 1 Week 2 Week 4 Week 8
Vector alone None 1 · 1011 None 5.0 – 1.0 6.6 – 1.0 5.9 – 0.6 No sample
Low-titer NAb 1:2 1 · 1011 None < 1 < 1 < 1 No sample
Low-titer NAb + 50% EC 1:2 1 · 1011 1 · 1011 < 1 < 1 < 1 No sample
Low-titer NAb + 80% EC 1:2 1 · 1011 4 · 1011 < 1 < 1 < 1 No sample
Week 1 Week 2 Week 4 Week 8
Vector alone None 1 · 1011 None 7.0 – 3.1 11.5 – 3.2 12.8 – 5.5 12.8 – 4.7
95% EC None 1 · 1011 1.8 · 1012 7.9 – 2.7 10.5 – 3.5 13.0 – 4.5 12.5 – 3.5
AAV8, adeno-associated virus serotype 8; EC, empty capsids; NAb, neutralizing antibody; VG, vector genomes.
Note: Serum from syngeneic (C57BL/6) mice, previously vaccinated with AAV8.A1AT vector, was used to passively transfer titratable
AAV8 neutralizing antibodies (NAbs) into previously untreated C57BL/6 FIX–/– mice. Mice received either no AAV8 NAb, or NAb
adequate to achieve low neutralizing titers (1:2), or to achieve moderate NAb titer (1:16). Subsequently, all mice were treated with the same
dose of FIXR338L expression vector. Various cohorts of mice received the scAAV8.FIXR338L GLP vector alone (*5–10% empty capsid
contamination) or the GLP vector mixed at a 1:1 ratio with AAV8 empty capsids or the GLP vector.
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spleen, vector copy numbers in cardiac and skeletal muscle
(which are relatively end-differentiated tissues with minimal
turnover) remained relatively stable from the 3-week evalua-
tion through the last evaluation at 18 weeks. The heart remained
a relatively high site of extrahepatic vector distribution at
weeks 10 and 18, although 120- to 150-fold lower than in the
liver. At the week 10 and 18 time points, skeletal muscle
contained the greatest concentration of vector amongst the
extrahepatic tissues.
Discussion
Hemophilia B has joined the list of conditions for which
clinical improvement has been achieved by gene therapy.29
The partial correction of the inherited enzyme deficiency in
the SJCRH/UCL trial has been persistent and associated
with a decrease in clinically apparent bleeding. There is a
limitation to the approach used, however, because a dose of
2 · 1012 VG/kg that can achieve 3–6% plasma factor IX
activity (correction to the moderate to mild hemophilia
range) is associated with elevations of serum liver trans-
aminases. Elevations in liver enzymes (associated with liver
inflammation and injury) were controlled in these subjects
with a course of corticosteroid immunosuppression therapy.
The investigators have described the observed hepatic in-
flammation as a manageable toxicity. Nevertheless, the
clinical trial populations for the phase 1/2 trials were care-
fully selected, and approaches that might avoid the need to
use vector doses associated with hepatic inflammation are
desirable. This is particularly the case because > 85% of the
U.S. severe hemophilia population over the age of 30 are
seropositive due to hepatitis B and C exposure; the majority
of those have active disease as evidenced by hepatitis virus
RNA on serum PCR testing.
The current standard of therapy for children with severe
hemophilia (which has not been universally adopted for
adults with severe hemophilia) is prophylactic replacement
with clotting factor protein with a goal to ensure that plasma
levels remain in at least the moderate hemophilia range
( > 1% factor IX activity) at most times. This approach does
not completely convert the severe bleeding phenotype to
that observed in moderate hemophilia.30 Opinion in the
hemophilia community proposes the idea that complete
protection from spontaneous joint hemorrhage is the ap-
propriate goal for hemophilia care, rather than a partial
conversion to a moderate bleeding tendency.31 An analysis
of bleeding in individuals with hemophilia A and clotting
factor levels between 1 and 40% demonstrated an 18% re-
duction in joint bleeding with every percent increase in
baseline factor level. The analysis of this population pre-
dicted a nearly zero risk for joint bleeding with a baseline
factor level of 15% and higher.32 To achieve this degree of
disease correction by gene therapy, while avoiding vector
doses that approach or exceed those already associated with
hepatic inflammation in two human trials, ongoing im-
provement of AAV.FIX vector efficiency is required. The
preclinical program described here demonstrates that the
incorporation of gain-of-function factor IX variants at amino
acid 338 can improve circulating factor IX activity. The
modified FIX proteins demonstrated differences in the level
of circulating FIX activity in the animal setting, as well as
nuances in protein expression and the ratio of activity/
antigen. Our extended studies of transgenic expression of
FIXR338L achieved equivalent or improved hemostatic
correction with lower exposure to vector than is required
when a vector expressing WTFIX is used. Of particular
importance is that the protection against bleeding-induced
joint disease was improved. The observation is supported by
reports in hemophilic animals of FIXR338A (using AAV or
adenoviral vectors in mice)11,12,33 or FIXR338L (using
lentiviral vectors in mice or AAV vector in dog)13–15,34
demonstrating increased clotting potential from these vari-
ants and the absence of thrombosis.
In the current study, survival was normal and evidence of
thrombosis was absent on extensive postmortem examina-
tion.35,36 This outcome is consistent with the experience in the
index case family expressing FIXR338L; clinical thrombosis
was experienced by affected members with factor IX activity
> 700–800% of normal but not in the carrier mother expressing
> 300% factor IX Padua.10 Of note, supraphysiological ex-
pression of transgenic factor VII or factor IX in mouse models
has led to thromboembolic premature death in some previous
reports.35,36 In our intravenous administration dose–response
study of FIXR338L expression, 100% of mice that survived the
initial anesthesia and vector administration subsequently lived
throughout 8 months of follow-up; this included 12 of 12 mice
stably expressing 80–180% FIXR338L activity and 7 of 7 mice
stably expressing 300–550% FIXR338L activity.
The substitution of a variant of the factor IX protein
introduces the potential risk of immune response to neoe-
pitopes in the factor IX transgene. Clinically, inhibitor an-
tibodies arise in only *2–4% of individuals with severe
hemophilia B after exogenous factor IX replacement, al-
though the risk is higher in individuals with complete or
large gene deletions. Examination of the Factor IX Mutation
Database reveals that individuals with missense mutations
arising from a single nucleotide variance from wild-type
factor IX essentially do not develop inhibitors in the setting
of exogenous protein replacement; a single patient with a
missense substitution complicated by inhibitor is described
among the 1095 unique F9 variants and 3713 individual
cases in the database37 (http://www.factorix.org/). All mice
used in this report had a factor IX null phenotype. Only
individuals who have extensive exposure to factor IX ( > 150
treatment days) without inhibitor development will partici-
pate in phase 1 trials that use this sequence variation.
On the basis of the available preclinical safety and effi-
cacy data reported here, we are currently investigating the
liver-directed vector incorporating FIXR338L (scAAV8
.FIXR338L, now given the designation BAX335) in a hu-
man clinical trial. Manufacturing using scalable suspension
cell culture and chromatographic purification resulted in
scAAV8 vector clinical stocks with less than 10% empty
particle contamination. The dose-escalation design of the
ongoing trial has been chosen to target steady state clinical
factor IX expression at not greater than 40% of normal
factor IX levels for this phase 1/2 safety study. In addition,
we demonstrate that the addition of wild-type empty AAV8
capsids to the scAAV8.FIXR338L/BAX335 vector prepa-
ration did not provide any evident benefit (e.g., to circum-
vent AAV8 NAbs) under the experimental conditions used.
A report by Mingozzi and colleagues suggested that AAV
empty capsids might improve transduction in the presence
of AAV NAbs by providing ‘‘decoy’’ particles to remove
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AAV NAbs, allowing therapeutic particles to infect with
less interference from AAV Nabs.28 There are a number of
differences in the experimental conditions used in this paper
and those of Mingozzi and colleagues. These include dif-
ferences in vector-manufacturing methods (it is not possible
to discern whether their vector stocks contain empty AAV
particles in addition to those intentionally supplemented), a
higher empty capsid exposure supplemented in their study,
and the source of NAb used for the passive transfer of
AAV8 NAb (human IVIG in their study compared with
specific anti-AAV8 arising after AAV8 infection under our
conditions). Given that the only vector-related toxicity that
has been observed to date in human trials of AAV gene
therapy for hemophilia B is a dose-related immune response
to the AAV capsid, our results support our strategy of
generating rAAV8 stocks with minimal empty AAV parti-
cles as desirable to avoid immune activation.
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